Ucb Biopharma Srl

This phase 3 study tested the drug bimekizumab in 133 Chinese adults with moderate to severe plaque psoriasis. Participants received either bimekizumab or a placebo for 16 weeks. The main goals were to see if bimekizumab could clear at least 90% of psoriasis (PASI90) and achieve …

This early-phase trial tested a new biologic drug called UCB1381 in 109 people, first in healthy volunteers and then in those with moderate to severe atopic dermatitis (eczema). The goal was to check safety and see if it improves eczema symptoms. Participants received either the …

This study tests whether certolizumab pegol (Cimzia), a drug already used for arthritis, can reduce flares of anterior uveitis—a painful eye inflammation—in people with axial spondyloarthritis who have had uveitis before. About 89 adults with active axial spondyloarthritis and a …

This study looked at the long-term safety and effectiveness of bimekizumab in adults with active psoriatic arthritis. Over 1,100 people who completed earlier studies received the drug and were monitored for side effects and disease symptoms. The goal was to see if bimekizumab rem…

This Phase 3 trial tested bimekizumab, a drug that targets inflammation, in 509 adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses and tunnels. Participants received either bimekizumab or a placebo over 16 weeks. The m…

This study tested a drug called bimekizumab in 505 adults with moderate to severe hidradenitis suppurativa, a chronic skin condition that causes painful lumps. The main goal was to see if the drug reduces the number of inflamed lumps by at least half after 16 weeks, compared to a…

This study tested two doses of bimekizumab, a drug that targets inflammation, in 41 adolescents aged 12 to 17 with moderate to severe plaque psoriasis. The main goals were to measure how the drug behaves in the body and to check its safety. Researchers also looked at how well it …

This study tested a new drug called bimekizumab in 567 adults with moderate to severe plaque psoriasis. Participants received either bimekizumab, a placebo, or another active drug. The main goal was to see how well bimekizumab cleared skin lesions after 16 weeks. Results showed s…

This phase 3 study tested bimekizumab, a drug given by injection, against a placebo in 435 adults with moderate to severe plaque psoriasis. The main goal was to see how many people achieved at least 90% skin clearing after 16 weeks. The trial also looked at complete clearing and …

This Phase 3 trial tested bimekizumab against secukinumab and placebo in 743 adults with moderate to severe plaque psoriasis. The main goal was to see how many patients achieved complete skin clearance (PASI100) at 16 weeks. Bimekizumab showed superior results compared to secukin…

This study tested a new medicine called bimekizumab against an existing drug (adalimumab) in 478 adults with moderate to severe plaque psoriasis. The goal was to see if bimekizumab could clear more skin at 16 weeks. Participants received either bimekizumab or adalimumab, and then…

This study looked at the long-term safety and tolerability of bimekizumab in over 1,300 adults with moderate to severe plaque psoriasis. Participants who completed earlier studies received bimekizumab injections over several years. The main goal was to track side effects and see …

This study tested whether people with generalized myasthenia gravis (gMG) can safely and effectively use an auto-injector to give themselves the drug zilucoplan at home. Thirty-one adults who were already on a stable dose of zilucoplan took part. The main goal was to see if they …

This Phase 2 trial tested the drug bimekizumab in 49 adults with moderate to severe plaque psoriasis. Participants received either bimekizumab or a placebo, and researchers measured how well the drug cleared skin and how long it stayed in the body. The goal was to see if bimekizu…

This study tested a drug called bimekizumab in 852 adults with active psoriatic arthritis, a condition causing joint pain, swelling, and skin patches. Participants received either bimekizumab, a placebo, or an existing treatment (adalimumab). The main goal was to see if bimekizum…

This Phase 3 trial tested bimekizumab, a drug given by injection, against a placebo in 400 adults with active psoriatic arthritis who had not responded well to TNF-alpha inhibitors. The study aimed to see if bimekizumab could reduce joint pain and swelling and improve daily funct…

This phase 3 study tested the drug bimekizumab against a placebo in 274 adults with active nonradiographic axial spondyloarthritis, a form of arthritis that causes back pain but doesn't appear on X-rays. Participants received injections of either the drug or a placebo over severa…

This study tested a drug called bimekizumab in 332 adults with active ankylosing spondylitis, a type of arthritis that causes back pain and stiffness. Participants received either the drug or a placebo injection. The goal was to see if the drug could reduce symptoms like pain and…

This study tested a drug called rozanolixizumab in 200 adults with generalized myasthenia gravis, a condition that causes muscle weakness. The goal was to see if the drug improves daily activities and is safe compared to a placebo. Participants received either the drug or a dummy…

This study tested an experimental oral drug, UCB0599, in 496 people with early-stage Parkinson's disease. The goal was to see if the drug could safely slow down the worsening of symptoms over 18 months compared to a placebo. Participants were randomly assigned to receive either t…

This study looked at the long-term safety and tolerability of the drug brivaracetam in 84 children and young adults (ages 2 to 26) with childhood or juvenile absence epilepsy. Participants who had already been in a previous study were given brivaracetam and monitored for side eff…

This Phase 3 trial tested whether adding brivaracetam (Briviact) to existing epilepsy medications could safely reduce partial seizures in adults aged 16 to 80. About 449 participants who still had frequent seizures despite taking 1 or 2 other drugs were randomly assigned to recei…

This study tested whether people with generalized myasthenia gravis could safely switch from intravenous (IV) infusions of complement inhibitors to daily injections of zilucoplan. Twenty-six participants who were stable on IV therapy switched to the subcutaneous shot. The main fo…

This study tested a new drug called UCB9741 in healthy volunteers and people with moderate-to-severe atopic dermatitis (eczema). The goal was to check its safety and see if it can improve eczema symptoms. The trial involved 107 participants and compared the drug to a placebo.

This Phase 2 trial tested an experimental drug called UCB0022 in 207 people with advanced Parkinson's disease. The goal was to see if adding UCB0022 to standard treatment could reduce the daily hours spent in the 'OFF' state, when Parkinson's symptoms return. Participants took ei…

This study tested a new drug called UCB0022 in 100 healthy volunteers and people with Parkinson's disease. The main goal was to check if the drug is safe and how the body processes it. This is an early-stage trial, so it does not prove the drug works for Parkinson's symptoms yet.

This study tested whether 62 people with generalized myasthenia gravis could learn to self-administer the drug rozanolixizumab at home using a syringe driver or manual push. Participants were trained and then assessed on their ability to correctly give themselves the infusion. Th…

This early-stage trial tested the safety and tolerability of a new drug called UCB0022 (glovadalen) in 32 healthy adults from Caucasian, Japanese, and Chinese backgrounds. Participants received either the drug or a placebo in increasing doses. The study is complete and focused on…

This study looked at how much of the drug rozanolixizumab appears in breast milk after a single dose. Fifteen healthy lactating women who had already decided to stop breastfeeding took part. Researchers measured drug levels in milk over 7 days to estimate how much a baby might be…

This completed phase 1 study tested how quickly an inhaled form of alprazolam (Staccato) affects brain activity compared to intravenous midazolam and nasal diazepam. Fifty-five healthy adults received single doses of each drug in a crossover design. Researchers used EEG brain wav…

This early-stage study tested the safety and how the body processes a single dose of donzakimig in 32 healthy Chinese and Japanese adults. Participants received either the drug or a placebo, and researchers monitored for side effects and drug levels in the blood. The goal was to …

This study looked at whether giving the drug zilucoplan through a prefilled syringe or an auto-injector works the same in the body. It involved 14 healthy adults aged 18 to 55. The goal was to compare how the drug is absorbed and to check safety, not to treat any disease.

This study tested two different tablet forms of an experimental drug called UCB0022 in 14 healthy adults. The goal was to see how well each form is absorbed into the body and to check for any safety issues. Participants took a single dose of each tablet on separate occasions, and…

This early-stage study looked at how a new drug, UCB0599, is absorbed in healthy adults. It also checked if stomach acid levels affect absorption and tested safety in Japanese and Chinese participants. The goal was to gather information, not to treat any disease.

This early-stage study involved 18 healthy adults to see how a new tablet version of the drug minzasolmin is absorbed compared to an older capsule form, and whether food changes absorption. Participants took single doses under fasting or fed conditions. The study is complete and …

This early-stage trial tested the safety and tolerability of a single dose of UCB9741 in 40 healthy adults, including both Caucasian and Japanese participants. Half received the drug and half a placebo, with neither participants nor researchers knowing who got what. The study foc…